Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer: A multicenter prospective AGEO study

Archive ouverte

Palmieri, Lola-Jade | Dubreuil, Olivier | Bachet, Jean-Baptiste | Trouilloud, Isabelle | Locher, Christophe | Coriat, Romain | Moryoussef, Frederick | Landi, Bruno | Perkins, Géraldine | Hautefeuille, Vincent | Doat, Solène

Edité par CCSD ; Elsevier -

International audience. Background: Previous research on chemotherapy discontinuation has mainly focused on predictive factors and outcomes. Few data are available on the reasons for chemotherapy discontinuation. The main objective was to identify the reasons for chemotherapy discontinuation in patients with gastrointestinal cancer. The secondary objectives were to describe the announcement of chemotherapy discontinuation and the time between chemotherapy discontinuation and death.Methods: This prospective multicenter French cohort included patients with advanced gastrointestinal cancer, for whom chemotherapy was discontinued between May 2016 and January 2018.Results: One hundred and fourteen patients were analyzed. The first cause of chemotherapy discontinuation was the impairment of general condition (asthenia, cachexia). Complications such as sepsis, jaundice or occlusion, were the second most frequent cause. Progression was observed at chemotherapy discontinuation in two-thirds of cases. The announcement of the chemotherapy discontinuation was made formally in 74% of cases, with a follow-up by a palliative care team initiated in 50% of cases. Sixty-nine percent of the patients received chemotherapy during the last three months of life and 26% during the last month. The median time between chemotherapy discontinuation and death was 65 days (IQR: 36.5-109): 44% of patients died at the hospital, 39% in a palliative care unit and 16% at home.Conclusion: Impairment of general condition was the major reason for chemotherapy discontinuation in patients with gastrointestinal cancers. Complications such as jaundice, sepsis or occlusion, were important reasons for discontinuation and could explain our shorter time between chemotherapy discontinuation and death, compared to other oncology sub-specialties.

Suggestions

Du même auteur

Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer

Archive ouverte | Palmieri, Lola-Jade | CCSD

International audience. OBJECTIVES: Early tumor shrinkage (ETS) has been reported to be associated with survival of metastatic colorectal cancer (mCRC) patients. Our aim was to analyze long-term tumor-size evolution...

Major pitfalls of protein kinase inhibitors prescription: a review of their clinical pharmacology for daily use

Archive ouverte | Gougis, Paul | CCSD

International audience. Protein kinase inhibitors (PKI) are a growing class of anticancer agents. They are prescribed with flat doses, and their oral administration is associated with interindividual variability in ...

Syndrome de LYNCH : identification et prise en charge

Archive ouverte | Coffin, Elise | CCSD

International audience

Chargement des enrichissements...